Oxytocin-induced changes in free T3/free T4 ratio and relationship with quality of life in adults with obesity
Clicks: 1
ID: 328272
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #382 of 383 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 383 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
CONTEXT: Oxytocin (OXT) is an anorexigenic, anxiolytic, and antidepressant neurohormone under investigation for obesity treatment. Mechanisms underlying OXT psychological effects are not fully understood, and human data on OXT modulation of the thyroid axis are lacking. Our 8-week trial of intranasal OXT in adults with obesity showed improved mental health-related quality of life (MHQoL) measured by the Short-Form 36 Health Survey vs placebo. Increased T4 and decreased T3 have been linked to depression. The free (bioactive) T3 (fT3)/free T4 (fT4) ratio, a marker of thyroid function in euthyroid patients, is associated with improved mental health. OBJECTIVE: To determine whether 6 weeks of intranasal OXT vs placebo modulates (1) the thyroid axis and (2) the relationship between fT3/fT4 and MHQoL changes. DESIGN: Eight-week randomized clinical trial, secondary analysis. SETTING: Tertiary academic center. PARTICIPANTS: Sixty-one adults with obesity. INTERVENTIONS: Eight weeks of intranasal OXT (24 IU) 4× daily or placebo. MAIN OUTCOME MEASURES: Pre- and posttreatment fasting thyroid hormones (week 6) and MHQoL (week 8). RESULTS: Six weeks of intranasal OXT vs placebo impacted fT3/fT4 (treatment × time P = .045), with an increase in the OXT group (P = .048) and no change in the placebo group (P = .406). TSH, fT4, and fT3 did not change (P ≥ .154). OXT vs placebo impacted the relationship between fT3/fT4 (6 weeks) and MHQoL (8 weeks) changes (treatment × Δ[fT3/fT4] P = .023); increased fT3/fT4 was positively associated with MHQoL improvement (trend-level P = .088). CONCLUSION: Prolonged OXT vs placebo increased fT3/fT4 and impacted the relationship between fT3/fT4 and MHQoL changes, with a trend-level positive correlation between fT3/fT4 and MHQoL change scores. OXT action on fT3/fT4 may underpin OXT-induced mental health benefits. CLINICAL TRIAL REGISTRATION: NCT03043053.
| Reference Key |
openalex_W7212015858
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Francesca Galbiati, Marie‐Louis Wronski, Thomas Bitar, Athanasios Bikas, Hannah Lamont, Sarah Hiranandani, Katherine Holman, Kamryn T. Eddy, Elisa Asanza, Sarah Smith, Maged Muhammed, Franziska Plessow, Anna Aulinas, Elizabeth A. Lawson |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag291
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.